Key result
Statin-ARB combination therapy was associated with a lower risk of major adverse cardiovascular and cerebrovascular events compared with statin-ACEI therapy.
Why the study?
Does combination therapy with statins and ARBs reduce major adverse cardiovascular and cerebrovascular events compared to statins and ACEIs in adults with coronary heart disease?
Cohort (n=3,676)
Yes
Does combination therapy with statins and ARBs reduce major adverse cardiovascular and cerebrovascular events compared to statins and ACEIs in adults with coronary heart disease?
In patients with coronary heart disease, combination therapy with statins and ARBs is associated with a significantly lower risk of major adverse cardiovascular and cerebrovascular events compared to combination therapy with statins and ACEIs.
Answers are grounded in this paper and cite their sources.
Should not yet change statin-ACEI or ARB prescribing in CHD; leaves open potential ARB advantage requiring randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2018) conducted a cohort in Coronary heart disease (n=3,676). Statin-ARB combination therapy vs. Statin-ACEI combination therapy was evaluated on MACCE (major adverse cardiovascular and cerebrovascular events), a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), ischemic stroke, and revascularization (HR 0.69, 95% CI 0.59-0.81). Statin-ARB combination therapy was associated with a lower risk of major adverse cardiovascular and cerebrovascular events compared with statin-ACEI therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: